0001140361-16-084182.txt : 20161031 0001140361-16-084182.hdr.sgml : 20161031 20161031164321 ACCESSION NUMBER: 0001140361-16-084182 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20161031 DATE AS OF CHANGE: 20161031 EFFECTIVENESS DATE: 20161031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alcresta Therapeutics, Inc. CENTRAL INDEX KEY: 0001673510 IRS NUMBER: 452729951 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-264996 FILM NUMBER: 161962126 BUSINESS ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 100 CITY: NEWTON STATE: MA ZIP: 02462 BUSINESS PHONE: 617 431 3600 MAIL ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 100 CITY: NEWTON STATE: MA ZIP: 02462 FORMER COMPANY: FORMER CONFORMED NAME: Alcresta, Inc. DATE OF NAME CHANGE: 20160502 D/A 1 primary_doc.xml X0707 D/A LIVE 0001673510 Alcresta Therapeutics, Inc. ONE NEWTON EXECUTIVE PARK SUITE 100 NEWTON MA MASSACHUSETTS 02462 617 431 3600 DELAWARE None Alcresta, Inc. Corporation true 2011 Daniel Tasse One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Executive Officer Director Robert Gallotto One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Executive Officer Tasos Konidaris One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Executive Officer James Topper One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Director Stephen Krauss One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Director Jeremy Lack One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Director Alexey Margolin One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Director Steve Dubin One Newton Executive Park Suite 100 Newton MA MASSACHUSETTS 02462 Director William Scheinler One Newton Exectutive Park Suite 100 Newton MA MASSACHUSETTS 02462 Executive Officer Martin Paz One Newton Exectutive Park Suite 100 Newton MA MASSACHUSETTS 02462 Executive Officer Biotechnology Decline to Disclose 06b true 0001140361-16-069707 2016-03-22 false true false 0 50889675 50889675 0 Total amount offered and sold include securities sold in connection with the conversion of convertible promissory notes. false 13 0 0 1043927 false Alcresta Therapeutics, Inc. /s/ Tasos Konidaris Tasos Konidaris Chief Financial Officer 2016-10-31